🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
6.65
+0.95 (16.67%)
Nov 18, 2026, 4:00 PM EST - Market closed

Company Description

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins.

Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.

The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others.

Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells.

The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers.

Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Akari Therapeutics, Plc
Akari Therapeutics, logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees6
CEOAbizer Gaslightwala

Contact Details

Address:
401 East Jackson Street, Suite 3300
Tampa, Florida 33602
United States
Phone929 274 7510
Websiteakaritx.com

Stock Details

Ticker SymbolAKTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001541157
CUSIP Number00972G405
ISIN NumberUS00972G4055
Employer ID98-1034922
SIC Code2834

Key Executives

NamePosition
Abizer GaslightwalaChief Executive Officer, President and Director
Kameel D. FaragInterim Chief Financial Officer
Dr. Satyajit Mitra Ph.D.Executive Director and Head of Oncology
Vatnak Vat-Ho M.B.A.Chief Business Officer

Latest SEC Filings

DateTypeTitle
Nov 13, 2026SCHEDULE 13G/AFiling
Nov 12, 20268-KCurrent Report
Nov 12, 202610-QQuarterly Report
Nov 12, 2026SCHEDULE 13G/AFiling
Oct 30, 2026S-8Securities to be offered to employees in employee benefit plans
Oct 30, 20268-KCurrent Report
Oct 1, 2026DEF 14AOther definitive proxy statements
Oct 1, 20268-KCurrent Report
Aug 13, 20268-KCurrent Report
Aug 13, 202610-QQuarterly Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides